Engineered immune cells take aim at Hard-to-Treat cancers

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The study aims to see if the modified cells can be made safely and what side effects they cause. Up to 21 participants will receive the cells through an IV after a short course of chemotherapy.